• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Nxu Shares Are Trading Higher By Around 42%; Here Are 20 Stocks Moving Premarket

    12/14/23 8:27:24 AM ET
    $ADBE
    $ASYS
    $AUVI
    $BWV
    Computer Software: Prepackaged Software
    Technology
    Industrial Machinery/Components
    Technology
    Get the next $ADBE alert in real time by email

    Shares of Nxu, Inc. (NASDAQ:NXU) rose sharply in pre-market trading after the company signed a letter of intent outlining investment in Lynx Motors.

    Nxu, shares rose 42.1% to $0.0278 in pre-market trading.

    Here are some other stocks moving in pre-market trading.

    Gainers

    • XBP Europe Holdings, Inc. (NASDAQ:XBP) shares rose 150% to $14.20 in pre-market trading after declining around 20% on Wednesday.
    • Hanryu Holdings, Inc. (NASDAQ:HRYU) gained 34.8% to $1.47 in pre-market trading after jumping 28% on Wednesday.
    • Meiwu Technology Company Limited (NASDAQ:WNW) shares gained 21.1% to $0.0850 in pre-market trading.
    • Codexis, Inc. (NASDAQ:CDXS) shares surged 20.5% to $2.52 in pre-market trading. Codexis announced achievement of gram-scale synthesis with its ECO Synthesis platform.
    • Esperion Therapeutics, Inc. (NASDAQ:ESPR) shares climbed 15.2% to $1.74 in pre-market trading. Esperion said that the FDA updated LDL-C lowering indication for NEXLETOL (bempedoic acid) tablet and NEXLIZET (bempedoic acid and ezetimibe) tablet.
    • Blue Water Biotech, Inc. (NASDAQ:BWV) shares rose 14.9% to $0.3109 in pre-market trading after gaining 7% on Wednesday.
    • Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) gained 14.6% to $1.33 in pre-market trading after falling 15% on Wednesday.
    • Nubia Brand International Corp. (NASDAQ:NUBI) rose 13.8% to $11.00 in pre-market trading after falling 9% on Wednesday.
    • Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) shares gained 11.1% to $0.19 in pre-market trading.

    Losers

    • Amtech Systems, Inc. (NASDAQ:ASYS) shares fell 26.4% to $4.41 in pre-market trading after the company reported worse-than-expected fourth-quarter sales results and issued first-quarter sales guidance below estimates.
    • Regis Corporation (NYSE:RGS) shares fell 22.6% to $7.20 in pre-market trading. NYSE will begin delisting proceedings against Regis Corp.
    • Cepton, Inc. (NASDAQ:CPTN) fell 22.4% to $3.08 in pre-market trading after the company posted downbeat third-quarter sales and issued weak FY23 revenue forecast.
    • NextPlay Technologies, Inc. (NASDAQ:NXTP) shares fell 18.4% to $1.28 in pre-market trading after jumping 68% on Wednesday.
    • Ocular Therapeutix, Inc. (NASDAQ:OCUL) shares fell 18% to $3.23 in pre-market trading. Ocular Therapeutix priced its public offering of 30.8 million common share stock at $3.25 per share for gross proceeds of $100.1 million.
    • Applied UV, Inc. (NASDAQ:AUVI) shares fell 14.5% to $1.59 in pre-market trading after declining around 10% on Wednesday. Applied UV teamed with Silver Cross Hospital in New Lenox, Illinois for the implementation of the groundbreaking Far-UVC Puro Protect 222nm fixtures in the hospital's Sterile Processing Department (SPD).
    • Shattuck Labs, Inc. (NASDAQ:STTK) fell 13.5% to $4.20 in pre-market after gaining 130% on Wednesday. Shattuck Labs announced initial topline dose-expansion data from its ongoing Phase 1A/B trial of SL-172154 in combination with Azacitidine (AZA) in frontline high-risk myelodysplastic syndromes (HR-MDS) and TP53 mutant (TP53m) acute myeloid leukemia (AML) patients.
    • Phio Pharmaceuticals Corp. (NASDAQ:PHIO) fell 11.8% to $0.6873 in pre-market trading after declining 9% on Wednesday. Phio Pharmaceuticals recently announced it will exercise warrants for $2.8 million in gross proceeds.
    • Intensity Therapeutics, Inc. (NASDAQ:INTS) shares fell 8.4% to $9.05 in pre-market trading after jumping 22% on Wednesday. Intensity Therapeutics recently named Joseph Talamo as CFO.
    • Adobe Inc. (NASDAQ:ADBE) fell 6.1% to $586.38 in pre-market trading. Adobe posted upbeat earnings for its fourth quarter, but issued weak sales forecast for full-year 2024.

     

    Now Read This: Lennar Gears Up For Q4 Print; Here's A Look At Recent Price Target Changes By The Most Accurate Analysts

    Get the next $ADBE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADBE
    $ASYS
    $AUVI
    $BWV

    CompanyDatePrice TargetRatingAnalyst
    Adobe Inc.
    $ADBE
    3/26/2026Mkt Perform
    William Blair
    Adobe Inc.
    $ADBE
    3/16/2026Buy → Hold
    Argus
    Adobe Inc.
    $ADBE
    3/13/2026$275.00Overweight → Equal Weight
    Barclays
    Adobe Inc.
    $ADBE
    3/13/2026$375.00 → $285.00Market Perform
    BMO Capital Markets
    Shattuck Labs Inc.
    $STTK
    3/6/2026$25.00Buy
    Needham
    Adobe Inc.
    $ADBE
    2/3/2026$330.00Overweight → Neutral
    Piper Sandler
    Shattuck Labs Inc.
    $STTK
    1/28/2026$15.00Overweight
    Piper Sandler
    Adobe Inc.
    $ADBE
    1/13/2026Outperform → Perform
    Oppenheimer
    More analyst ratings

    $ADBE
    $ASYS
    $AUVI
    $BWV
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for NEXLIZET issued to ESPERION THERAPS INC

    Submission status for ESPERION THERAPS INC's drug NEXLIZET (SUPPL-16) with active ingredient BEMPEDOIC ACID; EZETIMIBE has changed to 'Approval' on 03/22/2024. Application Category: NDA, Application Number: 211617, Application Classification: Efficacy

    3/25/24 4:41:30 AM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for NEXLIZET issued to ESPERION THERAPS INC

    Submission status for ESPERION THERAPS INC's drug NEXLIZET (SUPPL-17) with active ingredient BEMPEDOIC ACID; EZETIMIBE has changed to 'Approval' on 03/22/2024. Application Category: NDA, Application Number: 211617, Application Classification: Efficacy

    3/25/24 4:41:37 AM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for NEXLETOL issued to ESPERION THERAPS INC

    Submission status for ESPERION THERAPS INC's drug NEXLETOL (SUPPL-13) with active ingredient BEMPEDOIC ACID has changed to 'Approval' on 03/22/2024. Application Category: NDA, Application Number: 211616, Application Classification: Efficacy

    3/25/24 4:41:29 AM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADBE
    $ASYS
    $AUVI
    $BWV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Lindstrom Richard L Md bought $461,354 worth of shares (60,229 units at $7.66), increasing direct ownership by 32% to 246,933 units (SEC Form 4)

    4 - OCULAR THERAPEUTIX, INC (0001393434) (Issuer)

    2/24/26 6:13:03 PM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Asher Daniel bought $191,162 worth of shares (15,540 units at $12.30) (SEC Form 4)

    4 - EKSO BIONICS HOLDINGS, INC. (0001549084) (Issuer)

    2/20/26 4:57:37 PM ET
    $EKSO
    Industrial Machinery/Components
    Industrials

    Large owner Asher Daniel bought $11,520 worth of shares (1,200 units at $9.60) (SEC Form 4)

    4 - EKSO BIONICS HOLDINGS, INC. (0001549084) (Issuer)

    2/19/26 4:03:47 PM ET
    $EKSO
    Industrial Machinery/Components
    Industrials

    $ADBE
    $ASYS
    $AUVI
    $BWV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    William Blair resumed coverage on Adobe

    William Blair resumed coverage of Adobe with a rating of Mkt Perform

    3/26/26 8:44:26 AM ET
    $ADBE
    Computer Software: Prepackaged Software
    Technology

    Adobe downgraded by Argus

    Argus downgraded Adobe from Buy to Hold

    3/16/26 8:34:16 AM ET
    $ADBE
    Computer Software: Prepackaged Software
    Technology

    Adobe downgraded by Barclays with a new price target

    Barclays downgraded Adobe from Overweight to Equal Weight and set a new price target of $275.00

    3/13/26 8:44:39 AM ET
    $ADBE
    Computer Software: Prepackaged Software
    Technology

    $ADBE
    $ASYS
    $AUVI
    $BWV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Bender Lewis H

    4 - INTENSITY THERAPEUTICS, INC. (0001567264) (Issuer)

    3/30/26 5:29:06 PM ET
    $INTS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3 filed by new insider Xia Changbin

    3 - Meiwu Technology Co Ltd (0001787803) (Issuer)

    3/25/26 3:30:11 PM ET
    $WNW
    Catalog/Specialty Distribution
    Consumer Discretionary

    SEC Form 3 filed by new insider Yang Hanwu

    3 - Meiwu Technology Co Ltd (0001787803) (Issuer)

    3/25/26 3:27:20 PM ET
    $WNW
    Catalog/Specialty Distribution
    Consumer Discretionary

    $ADBE
    $ASYS
    $AUVI
    $BWV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Meiwu Technology Company Limited Announces 1-For-100 Reverse Share Split

    SHENZHEN, China, April 1, 2026 /PRNewswire/ -- Meiwu Technology Company Limited ("WNW" or the "Company"), (NASDAQ:WNW) today announced that it will effect a reverse share split of its outstanding ordinary shares, no par value (the "Ordinary Shares"), at a ratio of 1-for-100. Our Ordinary Shares will begin trading on a reverse share split-adjusted basis at the opening of The Nasdaq Capital Market ("Nasdaq") on April 6, 2026. Following the reverse share split, the Ordinary Shares will continue to trade on Nasdaq under the symbol "WNW" with the new CUSIP number, G9604C131. The reverse share split is expected to lead the Company's Ordinary Shares to trade at approximately 100 times the price per

    4/1/26 8:50:00 AM ET
    $WNW
    Catalog/Specialty Distribution
    Consumer Discretionary

    Ocular Therapeutix™ to Present Additional SOL-1 Data and Analyses at Upcoming Scientific Conferences in April

    BEDFORD, Mass., April 01, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), an integrated biopharmaceutical company committed to redefining the retina experience, today announced participation in several upcoming scientific conferences in April 2026. Ocular plans to present additional data and analyses from the SOL-1 Phase 3 superiority clinical trial of AXPAXLI™ (also known as OTX-TKI), for the treatment of wet age-related macular degeneration (wet AMD). Upcoming Scientific Conferences: 14th Annual Vit-Buckle Society (VBS) Meeting: April 9 - 11, 2026Las Vegas, Nevada Symposium Title: Redefining the Management of Neovascular AMDSymposium Date/Time: Saturday, Ap

    4/1/26 7:00:00 AM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Esperion to Participate in 25th Annual Needham Virtual Healthcare Conference

    ANN ARBOR, Mich., March 31, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that the company will be participating in the webcasted 25th Annual Needham Virtual Healthcare Conference on April 13, 2026, at 9:30 a.m. ET. The live webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after the completion of the call and will be archived on the Company's website for approximately 90 days. Esperion TherapeuticsEsperion Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and delivering innovative cardiometabolic and rare/orphan disease therap

    3/31/26 8:00:00 AM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADBE
    $ASYS
    $AUVI
    $BWV
    SEC Filings

    View All

    SEC Form PRER14C filed by Ekso Bionics Holdings Inc.

    PRER14C - EKSO BIONICS HOLDINGS, INC. (0001549084) (Filer)

    3/30/26 7:38:58 PM ET
    $EKSO
    Industrial Machinery/Components
    Industrials

    Phio Pharmaceuticals Corp. filed SEC Form 8-K: Other Events

    8-K - Phio Pharmaceuticals Corp. (0001533040) (Filer)

    3/30/26 7:15:34 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Intensity Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - INTENSITY THERAPEUTICS, INC. (0001567264) (Filer)

    3/27/26 4:13:39 PM ET
    $INTS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ADBE
    $ASYS
    $AUVI
    $BWV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Shattuck Labs Inc.

    SC 13D/A - Shattuck Labs, Inc. (0001680367) (Subject)

    12/6/24 9:03:38 PM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Ocular Therapeutix Inc.

    SC 13G/A - OCULAR THERAPEUTIX, INC (0001393434) (Subject)

    11/14/24 5:49:38 PM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Ekso Bionics Holdings Inc.

    SC 13G - EKSO BIONICS HOLDINGS, INC. (0001549084) (Subject)

    11/14/24 3:29:01 PM ET
    $EKSO
    Industrial Machinery/Components
    Industrials

    $ADBE
    $ASYS
    $AUVI
    $BWV
    Financials

    Live finance-specific insights

    View All

    Adobe Delivers Record Q1 Results

    AI-first ARR more than triples year over year Total subscription revenue and RPO increases 13% year over year Record Q1 operating cash flows of $2.96 billion Adobe (NASDAQ:ADBE), the global technology leader that unleashes creativity and productivity for individuals and businesses through innovative platforms and tools, today reported financial results for its first quarter FY2026 ended Feb. 27, 2026. "Adobe delivered record Q1 results with AI-first ARR more than tripling year over year and subscription revenue growing 13 percent," said Shantanu Narayen, chair and CEO, Adobe. "Our mission to empower everyone to create represents an even larger opportunity as content powers all e

    3/12/26 4:05:00 PM ET
    $ADBE
    Computer Software: Prepackaged Software
    Technology

    Codexis Reports Fourth Quarter and Fiscal Year 2025 Financial Results

         Q4 revenue of $38.9 million, total revenue of $70.4 million for the fiscal year ended December 31, 2025 Ended year with $78.2 million in cash, cash equivalents and short-term investments, runway through 2027 Completed $37.8 million Technology Transfer Agreement with Merck REDWOOD CITY, Calif., March 11, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex therapeutics, today announced financial results for the fourth quarter and year ended December 31, 2025, and provided a business update. "Throughout 2025, we made significant strides in demonstrating the importance of our ECO Synthesis

    3/11/26 4:05:00 PM ET
    $CDXS
    Major Chemicals
    Industrials

    Esperion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

    – FY25 Total Revenue Grew 21% Y/Y to $403.1 Million; FY25 U.S. Net Product Revenue Grew 38% Y/Y to $159.6 Million – – Q4 2025 U.S. Net Product Revenue Grew ~38% Y/Y to $43.7 Million; Q4 2025 Total Revenue Grew 144% Y/Y to $168.4 Million – – Q4 Retail Prescription Equivalents Grew 34% Y/Y and 11.3% Q/Q – – Agreement to Acquire Corstasis Therapeutics to Accelerate Growth and Expand Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray) – – Conference Call and Webcast Today at 8:00 a.m. ET – ANN ARBOR, Mich., March 10, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today reported financial results for the fourth quarter and full year ended December 31, 2025, and highlighted co

    3/10/26 6:00:00 AM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ADBE
    $ASYS
    $AUVI
    $BWV
    Leadership Updates

    Live Leadership Updates

    View All

    Phio Pharmaceuticals Announces Participation in Third Annual DealFlow Discovery Conference

    Phio's Presentation to take place on Wednesday January 28, 2026 at 9 AM ETKing of Prussia, Pennsylvania--(Newsfile Corp. - January 26, 2026) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today announced that it will participate in the DealFlow Discovery Conference, taking place January 28-29, 2026 at the Borgata Hotel in Atlantic City, NJ.Robert Bitterman, CEO and Chairman of the Board of Phio Pharmaceuticals will deliver a company presentation on January 28th at 9 AM in Borgata Hotel Room #1 and the management team will be avai

    1/26/26 8:15:00 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ocular Therapeutix™ Appoints David W. Robinson as Global Chief Commercial Officer

    Accomplished global commercial leader with deep expertise in retina drug launches Primary architect for the industry-defining launch of EYLEA® while at Regeneron Most recently served as Chief Marketing Officer, Global Ophthalmology at Merck BEDFORD, Mass., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ:OCUL, "Ocular")), an integrated biopharmaceutical company committed to redefining the retina experience, today announced that David W. Robinson has agreed to join the Company as Global Chief Commercial Officer. The appointment of Mr. Robinson, a proven commercial leader with a history of launching category-defining therapies, strategically positions Ocular for success

    1/21/26 7:00:00 AM ET
    $OCUL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Esperion Appoints Industry Veteran John Harlow as Chief Commercial Officer

    – Brings Extensive Executive Leadership Driving Commercial Strategies That Enhance Sales and Marketing Performance – ANN ARBOR, Mich., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced the appointment of John Harlow as the Company's Chief Commercial Officer, effective November 17, 2025. Mr. Harlow will join Esperion's Executive Leadership Team and will report directly to Sheldon Koenig, President and CEO of Esperion.    "We are thrilled to welcome John as our Chief Commercial Officer at such a pivotal time in Esperion's growth, as we continue to expand adoption of our products in the U.S. and increase our global footprint," said Koenig. "John's deep domain expertise

    11/4/25 8:00:00 AM ET
    $ESPR
    Biotechnology: Pharmaceutical Preparations
    Health Care